Biotech and Pharmaceuticals
FDA taps biotech industry veteran as RFK Jr.’s top drug regulator
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration said on Monday it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator. Tidmarsh, an adjunct professor of pediatrics and neonatology […]
Read More
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images For well over a decade, Grace Hamilton, 27, experienced hair loss, heavy periods, infrequent menstrual cycles, mental health issues and difficulty losing weight without knowing why. It wasn’t until 2021 when she was diagnosed with […]
Read More
Sarepta shares plunge 40% as future of its gene therapy appears at risk
Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Michael Nagle | Bloomberg | Getty Images Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The […]
Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]
Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]
Read More
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]
Read More
FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday. The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]
Read More
Trump’s 200% tariff threat leaves pharma firms scrambling with scenario planning
Shelf of pharmaceutical products. D3sign | Moment | Getty Images The pharmaceutical industry is scrambling with scenario planning as U.S. President Donald Trump’s 200% tariff proposal threatens to drive up drug prices and rip out corporate profit margins. The president once again warned on Tuesday that long-awaited industry-wide tariffs would be announced “very soon” after […]
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]
Read More
Merck shells out $10 billion for London-based lung therapy firm Verona
Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]
Read More